SOURCE: ConjuGon, Inc.

March 08, 2006 09:00 ET

ConjuGon® to Present at BIO and Begin Preclinical Testing

MADISON, WI -- (MARKET WIRE) -- March 8, 2006 --ConjuGon® announces today that it was selected to present at BIO 2006. BIO 2006, the world's largest biotechnology convention, will be held April 9-12, 2006 in Chicago. BIO 2006 will feature biotechnology and pharmaceutical companies working to develop therapies for some of the world's most devastating diseases and illnesses. ConjuGon officers also will present at the Sachs Associates Biotech Investing and Partnering Forum March 13-14, 2006 in Boston. Both venues bring together promising biotechnology companies, leading investors and pharmaceutical companies.

ConjuGon also is planning to begin preclinical testing with its first therapeutic this Spring. "We have come a long way in the past four years and are pleased to be making progress with our first therapeutic," said ConjuGon's CEO Christopher Price. "We are developing important therapeutics to help doctors in their fight against antibiotic resistance."

ConjuGon, a University of Wisconsin-Madison spin-off, has raised $3.75 million since its formation in 2002. ConjuGon is developing fundamentally new technologies to combat the growing epidemic of antibiotic-resistant bacteria. Antibiotic resistance is a medical crisis, globally responsible for hundreds of thousands of deaths each year. ConjuGon's core technology is a new way to kill unwanted and even multi-drug resistant bacteria. The company is located in the University Research Park in Madison.

Contact Information